Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study.
Tannir NM, Cho DC, Diab A, Sznol M, Bilen MA, Balar AV, Grignani G, Puente E, Tang L, Chien D, Hoch U, Choudhury A, Yu D, Currie SL, Tagliaferri MA, Zalevsky J, Siefker-Radtke AO, Hurwitz ME.
Tannir NM, et al. Among authors: puente e.
J Immunother Cancer. 2022 Apr;10(4):e004419. doi: 10.1136/jitc-2021-004419.
J Immunother Cancer. 2022.
PMID: 35444058
Free PMC article.
Clinical Trial.